Fulvestrant en la práctica clínica: análisis de efectividad en pacientes uruguayas con cáncer de mama HR+/HER2.

Introduction: Fulvestrant demonstrated benefits in overall survival and progression-free survival in patients with advanced breast cancer, who are hormone receptor-positive and human epidermal growth factor receptor 2 negative. The characteristics, evolution, and survival of patients with hormone receptor-positive, HER2-negative breast cancer treated with fulvestrant were evaluated according to the national treatment coverage protocols of the National Resources Fund, with the aim of understanding the efficacy of fulvestrant in patients treated in usual clinical practice and comparing our results with those from pivotal studies.

Methods: A database from the National Resources Fund covering the period from 2009 to 2022 was used.

[Cardiotoxicity from anti-HER-2 therapies in patients with HER-2 positive breast cancer].

Background: HER-2 positive (+) breast cancer (BC) accounts for 20-25% of BC, it is more aggressive, and it has a lower survival rate. Since the approval of trastuzumab in 1998, other HER-2-targeted therapies such as pertuzumab and trastuzumab emtansine (TDM1) have been introduced, improving patient survival. However, cardiotoxicity is an adverse effect of these treatments.

[Returning to work after diagnosis and treatment of breast cancer].

Background: Returning to work and performing housework tasks (HWT) is the final step in overcoming breast cancer (BC).

Objective: To assess whether clinical characteristics and type of treatment impact employment status and performance of HWT.

Material And Methods: A total of 119 patients diagnosed with early BC were enrolled.

Metastatic colorectal cancer: recent advances in its clinical management.

Colorectal cancer (CRC) is frequently complicated by metastatic disease, with the liver being the most common site of metastasis. Surgical resection is the only realistic cure for colorectal liver metastases; however only 10-25% of cases are initially resectable. The introduction of combination chemotherapy has improved survival rates by enabling 10-20% cases with previously unresectable hepatic metastases to become amenable to surgery.